chronic myeloid leukemia research hub
12 indexed studies · 9 currently recruiting
- recruitingTherapeutic exploratory (Phase II)
A Prospective Phase II Clinical Trial Evaluating the Efficacy and the Safety of Tyrosine Kinase Inhibitors Withdrawal After a Previous Two-step Dose Reduction in Patients With Chronic Myeloid Leukemia in Deep Molecular Remission
This study looks at whether adults with chronic myeloid leukaemia (CML) who have very low cancer levels can safely lower their daily tablet dose and eventually stop taking it. Doctors want to see if patients can stay healthy and cancer-free without needing lifelong medication and its side effects.
Czechia - authorisedTherapeutic exploratory (Phase II)
Efficacy of asciminib in chronic phase CML patients with T315l mutations
This clinical trial is testing a targeted medicine called asciminib (Scemblix) in adults with chronic myeloid leukaemia (CML). It focuses on people whose cancer cells carry a specific change called the T315I mutation, aiming to see if these daily tablets can successfully reduce leukaemia levels in the blood.
Germany - recruitingTherapeutic exploratory (Phase II)
A phase II, single-arm study of de-escalation and treatment-free remission in patients with chronic myeloid leukemia treated with nilotinib in first-line therapy followed by a second attempt after nilotinib and asciminib combination: DANTE study
This study looks at stopping leukaemia medication (Tasigna, Scemblix) in two stages for people with chronic myeloid leukaemia (CML). It aims to see if patients can stay well without treatment after initial drug therapy, and what happens if they need to restart or switch medications.
Italy - recruitingTherapeutic exploratory (Phase II)
Venetoclax after TKI to target persisting stem cells in CML
This study looks at a new way to treat Chronic Myeloid Leukaemia (CML). It's for people whose CML is well controlled with standard medicine. Researchers want to see if adding another drug, Venetoclax, can get rid of the remaining leukaemia cells that might be hiding in the bone marrow.
Germany - recruitingPHASE3
Study of Olverembatinib (HQP1351) in Patients With CML-CP
This study is looking at a new medicine called olverembatinib for people with a type of blood cancer called Chronic Myeloid Leukemia (CML-CP). It compares olverembatinib with an existing medicine, bosutinib, and also checks the new medicine for those with a specific gene change (T315I mutation).
United States · Australia · Belgium - recruitingPHASE1, PHASE2
A Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)
This study is testing a new medicine called TERN-701 for people with a type of blood cancer called Chronic Myeloid Leukemia (CML) that hasn't responded well to other treatments. It aims to check if the medicine is safe, what dose works best, and if it helps treat the cancer.
United States · Australia · France - recruitingNA
Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies in Chronic Myeloid Leukemia
This study looks at how medicines for Chronic Myeloid Leukemia (CML) interact with other drugs and herbal remedies. It aims to make sure patients get the most from their CML treatment by checking drug levels and making adjustments if needed.
France - recruiting
CML Pediatric ITK Response According to Molecular Identification at Diagnosis
This study looks at children with a type of blood cancer called Chronic Myeloid Leukaemia (CML). We're exploring if specific genetic changes can help predict how well children will respond to common CML medicines called TKIs. This could help doctors choose the best treatment.
France - active not recruitingPHASE2
2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients
This study looks at whether people with Chronic Myeloid Leukemia (CML) can successfully stop their nilotinib medicine a second or third time if their cancer has been well-controlled for a long time. It focuses on those who previously tried and weren't able to stop permanently.
Germany · Netherlands - authorisedTherapeutic exploratory (Phase II)
Safety and efficacy of treatment combination with ponatinib and asciminib in chronic myeloid leukemia patients resistant to ponatinib and/or asciminib
This study is looking at a new combination of two existing medicines, Scemblix and Iclusig, for people with chronic myeloid leukemia (CML). It aims to see how safe and effective this combination is when current treatments aren't working as well as they should.
Spain - recruitingPHASE2
Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial
This study looks at restoring healthy gut bacteria in people with blood cancers before a stem cell transplant. We're testing special capsules (IMT) against a dummy capsule to see if they improve gut health and reduce common problems like infections after transplant.
United Kingdom - recruitingPHASE1
A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
This study is looking at a new medicine called ELVN-001 for people with a type of blood cancer called Chronic Myeloid Leukaemia (CML). It aims to find the right dose and see how safe and effective it is, especially for those who haven't responded well to other treatments.
United States · Australia · Belgium